ADVM Adverum Biotechnologies Inc.

3.7
+0.07  (+2%)
Previous Close 3.63
Open 3.62
Price To Book 1.08
Market Cap 232613002
Shares 62,868,379
Volume 460,598
Short Ratio
Av. Daily Volume 281,140

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Development to be discontinued - noted November 1, 2018.
ADVM-043
Alpha-1 Antitrypsin (A1AT) Deficiency
Phase 2a negative data released June 2015 (met primary endpoint but increase in retinal thickness). As a result Phase 2b development will not proceed.
AVA-101
Wet age-related macular degeneration (Wet-AMD)
Phase 1 trial initiation announced November 19, 2018. Interim data due 1Q 2020.
ADVM-022
Wet age-related macular degeneration (Wet-AMD)

Latest News

  1. Adverum to Present at the 8th Annual SVB Leerink Global Healthcare Conference
  2. Adverum Biotechnologies Announces Presentation of Preclinical Long-Term Safety Data of ADVM-022 at 2019 Angiogenesis, Exudation, and Degeneration Conference
  3. Report: Developing Opportunities within Waste Connections, Performance Food Group, HealthEquity, PS Business Parks, Adverum Biotechnologies, and Bellicum Pharmaceuticals — Future Expectations, Projections Moving into 2019
  4. Adverum Biotechnologies Provides 2019 Outlook
  5. Adverum to Present at the 37th Annual J.P. Morgan Healthcare Conference
  6. What Bargains? Play 5 Stocks With Rising P/E Instead
  7. Is Adverum Biotechnologies, Inc. (ADVM) A Good Stock To Buy?
  8. Adverum Biotechnologies Appoints Mike Fitzgerald as Vice President, Human Resources
  9. Adverum Biotechnologies Announces Publication of Preclinical Long-Term Expression and Efficacy Data in Molecular Therapy
  10. Adverum Biotechnologies (ADVM) Reports Q3 Loss, Tops Revenue Estimates
  11. Adverum Biotechnologies: 3Q Earnings Snapshot
  12. Adverum Biotechnologies (ADVM) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
  13. Here's Why Adverum Biotechnologies Dropped as Much as 42.4% Today
  14. Apple, Cirrus Logic, GoPro, and More: Here’s Why These Stocks Are On the Move
  15. The Daily Biotech Pulse: Illumina Snaps Up Pacific Bioscience, Thumbs Down For Alkermes Depressive Disorder Drug